Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
Conditions
Brief summary
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regimen is called ICE and includes three drugs: ifosfamide, carboplatin, and etoposide. Pembrolizumab is currently Food and Drug Administration (FDA) approved for the treatment of some patients with melanoma, lung cancer and head and neck cancer, but has not yet been approved for the treatment of Relapsed/Refractory Hodgkin Lymphoma. The 'ICE' regimen of chemotherapy is currently FDA approved for the treatment of Relapsed/Refractory Hodgkin Lymphoma, but has not yet been investigated in combination with pembrolizumab for this disease. For patients who have a relapse of their Hodgkin's lymphoma, retreatment with chemotherapy followed by a stem cell transplant is recommended. We know that obtaining a complete remission (not able to detect any disease on scans) is very important prior to proceeding to the stem cell transplant. Patients with negative scans have a lower chance of the disease coming back and a higher chance of achieving a long-term cure.
Detailed description
PRIMARY OBJECTIVES: I. To determine the complete response rate by fludeoxyglucose- positron emission tomography/computed tomography (FDG-PET/CT) prior to autologous hematopoietic stem cell transplant (AHSCT) with the combination of pembrolizumab and ifosfamide, carboplatin, etoposide (ICE) salvage chemotherapy for relapsed/refractory Hodgkin lymphoma. SECONDARY OBJECTIVES: I. To determine the safety and tolerability of pembrolizumab in combination with salvage high-dose chemotherapy according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03. II. To estimate the event free survival (EFS) at 2 years from start of treatment. III. To estimate the overall survival (OS) at 2 years from start of treatment. TERTIARY OBJECTIVES: I. To characterize PD-1 pathway specific expression and correlate with response. II. To characterize serum biomarkers of immune and inflammatory response during treatment. III. To characterize levels of soluble PD-L1 related to treatment with pembrolizumab. IV. To characterize T-lymphocyte subset changes to treatment with pembrolizumab. V. To investigate the prevalence and clinical correlation of chromosome 9p24.1 mutations for this population. VI. To evaluate the effect on stem cell harvest following treatment with pembrolizumab. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3. After completion of study treatment, patients are followed up at 30 days, every 3 months for 2 years.
Interventions
DRUGCarboplatin
Given IV
DRUGEtoposide
Given IV
DRUGIfosfamide
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALPembrolizumab
Given IV
Sponsors
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Northwestern University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed diagnosis of classical Hodgkin lymphoma including nodular sclerosis, mixed cellularity, lymphocytic-rich, and lymphocyte depleted subtypes by the 4th edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues published in 2008 * Patients must have disease with FDG-PET/CT avidity * Patients must have relapsed/refractory disease, with at least one line of prior chemotherapy, but =\< 2 prior lines of treatment, for Hodgkin lymphoma; NOTE: Patients must not have had prior immune checkpoint inhibitors; however, there are no other limitations to prior agent or regimen types * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Patients must have adequate organ and bone marrow function within 10 days of registration, as defined below: * Absolute neutrophil count \>= 1,000/mcL (in the absence of granulocyte colony stimulating factor (GCSF) for \>= 14 days) * Platelets \>= 75,000/mcl (in the absence of platelet transfusion for \>= 14 days) * Hemoglobin \>= 7g/dL (transfusion permitted) * Total bilirubin =\< 2 x institutional upper limit of normal (ULN); if total bilirubin is \> 2 x ULN, the direct bilirubin must be normal * Aspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SPGT\]) =\< 2.5 x institutional ULN * Creatinine =\< 2 x ULN or creatinine clearance (CrCl) \> 30 ml/min * Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registration; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * Females of childbearing potential (FOCBP) should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \> 12 months) NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject * Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study
Exclusion criteria
* Patients who have had chemotherapy, radiotherapy, monoclonal antibody (mAb), or targeted small molecule therapy within 4 weeks of study registration are not eligible; those who have not recovered from adverse events (grade 1 or baseline) due to such agents administered more than 4 weeks earlier are not eligible * Patients may not be currently receiving any other investigational agents within 4 weeks of study registration * Patients must not have had prior exposure to any immune checkpoint inhibitors including anti-PD-1, anti-PD-L1 agents, anti-PD-L2 agents, or anti-CTLA-4 monoclonal antibodies * Patients must not have known central nervous system (CNS) involvement * Patients must not have had prior stem cell transplantation (autologous or allogeneic) * Patients must not have persistent diarrhea greater than National Cancer Institute (NCI) CTCAE grade 2 at the time of study registration, despite medical management * Patients must not have a history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, noninfectious pneumonitis * Patients with known immunodeficiency, known autoimmune disease, or concurrent use of immunomodulatory agents including systemic steroids within 7 days prior to registration, are ineligible * Patients must not have co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens; this includes, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Patients must not have a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer * Patients with known human immunodeficiency virus (HIV) infection or active TB (Bacillus tuberculosis) are not eligible * Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible * Patients must not have a hypersensitivity to pembrolizumab or any of its excipients * Patients must not have received a live vaccine within 30 days of registration Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed) * Patients must not be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment * Patients who are unwilling or unable to comply with the protocol or have known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial are not eligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate | Up to 59 days | To determine the complete response rate by FDG-PET/CT prior to AHSCT with the combination of pembrolizumab and ICE salvage chemotherapy for relapsed/refractory Hodgkin lymphoma. Response was assessed using Lugano criteria 2014. To address the primary aim, the proportion of patients with complete responses was calculated(defined as FDG-PET/CT Deauville score ≤ 3) as (number of responders) / (number of evaluable patients). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events | Up to 2 years | Evaluate the safety and tolerability of pembrolizumab in combination with ICE salvage high-dose chemotherapy by measuring the frequency and severity of adverse events by type, severity (grade), timing, and attribution to pembrolizumab which will be assessed according the NCI-CTCAE version 4.03. |
| Event Free Survival (EFS) | Up to 2 years | EFS will be defined as the length of time from treatment on protocol until the first occurrence of disease relapse, progression, re-initiation of cytotoxic chemotherapy, or death due to disease, or until last contact if the patient did not experience any of these, assessed up to 2 years. |
| Overall Survival (OS) | Up to 2 years | OS will be defined as time from study enrollment until death, or until last contact if the patient did not die, assessed up to 2 years. |
Countries
United States
Participant flow
Recruitment details
The first patient started treatment 04/24/2017. The study was designed to enroll patients with relapsed/refractory classical Hodgkin lymphoma following standard up-front chemotherapy. The study was closed to further enrollment on 10/29/2020 due to meeting accrual goal.
Participants by arm
| Arm | Count |
|---|---|
| Treatment Patients received treatment with combination pembrolizumab and ICE (ifosphamide, carboplatin, etoposide) salvage chemotherapy for 2 cycles (1 cycle = 21 days). Pembrolizumab 200 mg IV will be administered on day 1. Standard ICE salvage chemotherapy includes ifosfamide 5 g/m2 with equivalent dose of MESNA given over 24 hours by CIV on day 2, carboplatin AUC 5 IV with a maximum of 800 mg on day 2, and etoposide 100 mg/m\^2/day IV on days 1 to 3. G-CSF support administered 24 hours following completion of chemotherapy.
On Cycle 3 day1, patients received pembrolizumab monotherapy. An FDG-PET/CT will be obtained 14-22 days after pembrolizumab monotherapy to assess response by Deauville criteria. Patients with Deauville \</= 3 will proceed to AHSCT which may include a 4th optional cycle of Pembro-ICE prior to transplant per investigator discretion. Patients with Deauville \>3 will be treated per provider's discretion which may also include stem cell transplant. | 43 |
| Total | 43 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Autologous Stem Cell Transplant | Adverse Event | 1 |
| Autologous Stem Cell Transplant | Physician Decision | 1 |
| Autologous Stem Cell Transplant | Withdrawal by Subject | 2 |
| Follow-up | Patients still in follow-up | 15 |
| Treatment Cycles | Death | 1 |
| Treatment Cycles | Screen Fail | 2 |
| Treatment Cycles | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Treatment |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 42 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 7 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants |
| Race (NIH/OMB) White | 32 Participants |
| Sex: Female, Male Female | 27 Participants |
| Sex: Female, Male Male | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 42 |
| other Total, other adverse events | 42 / 42 |
| serious Total, serious adverse events | 17 / 42 |
Outcome results
Primary
Complete Response Rate
To determine the complete response rate by FDG-PET/CT prior to AHSCT with the combination of pembrolizumab and ICE salvage chemotherapy for relapsed/refractory Hodgkin lymphoma. Response was assessed using Lugano criteria 2014. To address the primary aim, the proportion of patients with complete responses was calculated(defined as FDG-PET/CT Deauville score ≤ 3) as (number of responders) / (number of evaluable patients).
Time frame: Up to 59 days
Population: Of the 42 registered study patients, 37 were evaluable for response.~To be evaluable for inclusion in the analysis to address the primary objective, patients must:~* have received at least dose of pembrolizumab AND~* have a FDG-PET/CT scan following cycle #3
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment | Complete Response Rate | Progressive Disease | 1 Participants |
| Treatment | Complete Response Rate | Complete Repsonse | 32 Participants |
| Treatment | Complete Response Rate | Partial Response | 4 Participants |
Secondary
Event Free Survival (EFS)
EFS will be defined as the length of time from treatment on protocol until the first occurrence of disease relapse, progression, re-initiation of cytotoxic chemotherapy, or death due to disease, or until last contact if the patient did not experience any of these, assessed up to 2 years.
Time frame: Up to 2 years
Secondary
Incidence of Adverse Events
Evaluate the safety and tolerability of pembrolizumab in combination with ICE salvage high-dose chemotherapy by measuring the frequency and severity of adverse events by type, severity (grade), timing, and attribution to pembrolizumab which will be assessed according the NCI-CTCAE version 4.03.
Time frame: Up to 2 years
Secondary
Overall Survival (OS)
OS will be defined as time from study enrollment until death, or until last contact if the patient did not die, assessed up to 2 years.
Time frame: Up to 2 years